23^rd Neuropharmacology Conference 2013

Official Satellite to the 2013 Meeting of the Society for Neuroscience

Sheraton San Diego Hotel and Marina| 7 -8 November 2013

Conference Chairs

Thomas C Sudhof, Stanford University, CA, USA
D James Surmeier, Northwestern University Medical School, IL, USA

Conference Organizing Committee

Karen E Duff, Taub Institute at Columbia University, NY, USA
John Isaac, Eli Lilly and Company, UK
Andy Randall, Universities of Exeter and Bristol, UK
Richard Wade-Martins, University of Oxford, UK

There is increasing evidence that neurodegenerative diseases have at their basis dysfunctions in the receptors and ion channels subserving synaptic communication. This would explain the cognitive decline and neurological and motor symptoms associated with a host of chronic disorders such as Alzheimer’s, Parkinson’s and Huntington’s diseases.

Understanding the cellular and molecular events underpinning such synaptic dysfunction is a key goal if we are to halt or even reverse the inexorable deterioration currently observed in these conditions. Accordingly, much insight has already been gleaned on the genetics, protein misfolding, cell death pathways and mitochondrial involvement in chronic neurodegenerative diseases. From this insight has come greater knowledge of the fundamentals of synaptic function, but more so an appreciation of the potential, not only for drug-based therapies, but also biological treatments, for example via stem cells.

This conference will bring together world experts addressing the very mechanisms of neurodegeneration and the prospects for treatments that such knowledge promises.

Topics

Posters are invited on the following conference themes:

• Synaptic dysfunction in Parkinson's disease
• Circuit and Synapse dysfunction in Alzheimer’s disease
• Protein misfolding, autophagy and synaptic dysfunction in neurodegenerative diseases
• Trans-synaptic prion-like spread of neurodegenerative processes
• Synaptic integration of iPS-derived neurons and their use in neurodegenerative disease
• Genetic and mitochondrial determinants of synaptic dysfunction in neurodegenerative disease
• Targeting synapses with therapeutics in neurodegenerative disease